Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02555306
Other study ID # 36-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 16, 2015
Est. completion date August 2017

Study information

Verified date January 2020
Source Santen Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration (AMD).


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Provide signed written informed consent

- Diagnosis of subretinal or intraretinal fluid secondary to exudative age-related macular degeneration

- Prior treatment in the study eye with any intravitreal anti-VEGF medication

- At least one lesion in the study eye that meets minimal pathology criteria

- Best corrected visual acuity of 65 to 20 ETDRS letters in the study eye

- Best corrected visual acuity of 20/200 or better in the fellow eye

- Reasonably clear media and some fixation in the study eye

Exclusion Criteria:

Ocular

- Use or anticipated use of any intravitreal, periocular or photodynamic therapy in the study eye for the treatment of AMD within a specified timeframe prior to Visit 1

- Uncontrolled or advanced glaucoma, chronic hypotony or vitrectomy in the study eye

- Evidence of any other ocular disease other than exudative age-related macular degeneration in the study eye that may confound the outcome of the study

- Need for ocular surgery in the study eye during the course of the study

- Presence or history of certain ocular or periocular pathology or conditions that could limit the ability to perform required study assessments in either eye and/or confound study results

Non-Ocular

- Allergy or hypersensitivity to study drug product, fluorescein dye or other study-related procedures and medications

- Current or history of certain systemic conditions, abnormalities or therapies that would render a subject a poor candidate for the study

- Participation in other investigational drug or device clinical trials within 30 days prior to randomization or planning to participate in other investigational drug or device clinical trials for the duration of the study

- Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions and men who do not agree to practice an acceptable method of contraception throughout the course of the study

- Unable to comply with study procedures or follow-up visits

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
0.5 mg of DE-122
DE-122 Injectable Solution
1.0 mg of DE-122
DE-122 Injectable Solution
2.0 mg of DE-122
DE-122 Injectable Solution
4.0 mg of DE-122
DE-122 Injectable Solution

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Santen Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Best Corrected Visual Acuity (BCVA) at Day 90. BCVA measures the acuteness or clearness of best-corrected vision in ETDRS (Early Treatment of Diabetic Retinopathy Study) letters, with a range of [0, 97] in ETDRS letters.
An increase in BCVA indicates an improvement in the best corrected vision.
Baseline (Day1) and Day 90.
Secondary Change From Baseline in Central Subfield Thickness (CST) at Day 90. Bioactivity measures include CST (µm) measured by SD-OCT. Bioactivity will be considered evident if a considerable decrease in CST is observed. Baseline (Day1) and Day 90.
See also
  Status Clinical Trial Phase
Recruiting NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536297 - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT04005352 - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Phase 3
Withdrawn NCT02873351 - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration Phase 2
Active, not recruiting NCT02802657 - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration Phase 4
Not yet recruiting NCT02864472 - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Phase 4
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT02035722 - Intravitreal Injections-related Anxiety Phase 2/Phase 3
Completed NCT01445548 - Sirolimus for Advanced Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01048476 - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT01174407 - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration N/A
Terminated NCT00712491 - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00345176 - Age-Related Eye Disease Study 2 (AREDS2) Phase 3
Completed NCT02140151 - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Phase 1/Phase 2
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT03166202 - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed NCT01397409 - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase 2
Recruiting NCT06174181 - Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration N/A